PDF(Pubmed)
Abstract：
UNASSIGNED: Following the c In the management of BPH, Tamsulosin is an example of a-adrenergic receptor blocker drug that is usually used. In addition, dutasteride is also a BPH drug that works as a group of 5 a reductase inhibitor. However, the weakness of long-term administration of a1-adrenergic receptor antagonists can result in upregulation of prostate smooth muscle cell contractility and expression of a-adrenergic mRNA receptors, resulting in hyperactivity and supersensitivity to a-agonists.
UNASSIGNED: Our study aimed to determine the effect of long-term administration of tamsulosin, dutasteride and tamsulosin-dutasteride combination on the contractility of prostate smooth muscle cells in BPH model rats.
UNASSIGNED: This study was designed using an experimental post test only method, control group design. It measured the contractility of prostate smooth muscle cells from samples obtained from the prostatic stroma of experimental animals adult male Rattus norvegicus Wistar strain induced BPH and administered tamsulosin 1 mg/kg/day, dutasteride 0.5 mg/kg/day, and a combination of continuous administration for 1, 6 and 12 consecutive days. Data were analyzed using one way ANOVA if the data distribution was normal or Kruskall Walis if the data distribution was abnormal.
UNASSIGNED: The effect of tamsulosin, dutasteride and the combination of tamsulosin with dutasteride on prostate smooth muscle cell contractility in experimental animals Rattus norvegicus Wistar strain showed that tamsulosin administration for six days, twelve days, and the combination of tamsulosin dutasteride for one day got statistically significant different result (p=0.016; p=0.006; p=0.029) compared to the negative control group. In addition, there was a difference between the tamsulosin and dutasteride combination group for 12 days compared to tamsulosin monotherapy for 6 days and 12 days (p=0.160; p=0.010).
UNASSIGNED: Continuous administration of monotherapy tamsulosin has an upregulation effect on the sixth to twelfth day. Decreased contractility of prostate smooth muscle cells occurs on the first day but will increase on the sixth to twelfth day. On the other hand, the results of our study also showed that the combination of tamsulosin and dutasteride gave the effect of reducing contractility and was most effective on day 12.
UNASSIGNED: Our study aimed to determine the effect of long-term administration of tamsulosin, dutasteride and tamsulosin-dutasteride combination on the contractility of prostate smooth muscle cells in BPH model rats.
UNASSIGNED: This study was designed using an experimental post test only method, control group design. It measured the contractility of prostate smooth muscle cells from samples obtained from the prostatic stroma of experimental animals adult male Rattus norvegicus Wistar strain induced BPH and administered tamsulosin 1 mg/kg/day, dutasteride 0.5 mg/kg/day, and a combination of continuous administration for 1, 6 and 12 consecutive days. Data were analyzed using one way ANOVA if the data distribution was normal or Kruskall Walis if the data distribution was abnormal.
UNASSIGNED: The effect of tamsulosin, dutasteride and the combination of tamsulosin with dutasteride on prostate smooth muscle cell contractility in experimental animals Rattus norvegicus Wistar strain showed that tamsulosin administration for six days, twelve days, and the combination of tamsulosin dutasteride for one day got statistically significant different result (p=0.016; p=0.006; p=0.029) compared to the negative control group. In addition, there was a difference between the tamsulosin and dutasteride combination group for 12 days compared to tamsulosin monotherapy for 6 days and 12 days (p=0.160; p=0.010).
UNASSIGNED: Continuous administration of monotherapy tamsulosin has an upregulation effect on the sixth to twelfth day. Decreased contractility of prostate smooth muscle cells occurs on the first day but will increase on the sixth to twelfth day. On the other hand, the results of our study also showed that the combination of tamsulosin and dutasteride gave the effect of reducing contractility and was most effective on day 12.
摘要：
未经证实：遵循c在BPH的管理中，坦索罗辛是通常使用的α-肾上腺素能受体阻断剂药物的实例。此外,dutasteride也是BPH药物，作为一组5a还原酶抑制剂。然而,β1-肾上腺素能受体拮抗剂长期给药的弱点可导致前列腺平滑肌细胞收缩性上调和α-肾上腺素能mRNA受体表达上调,导致对a-激动剂过度活跃和过敏。
未经评估：我们的研究旨在确定长期服用坦索罗辛的效果，研究目的:探讨盐酸达雄胺与坦索罗辛-达雄胺联合应用对BPH模型大鼠前列腺平滑肌细胞收缩性的影响.
UNASSIGNED：本研究是使用仅实验后测试方法设计的，对照组设计。它测量了从实验动物的前列腺基质中获得的前列腺平滑肌细胞的收缩力成年雄性褐家鼠Wistar菌株诱导的BPH并给予坦索罗辛1mg/kg/天，dutasteride0.5mg/kg/天，以及连续给药1、6和12天的组合。如果数据分布正常，则使用单向ANOVA分析数据，如果数据分布异常，则使用KruskallWalis分析数据。
未经批准：坦索罗辛的作用，杜他雄胺和坦索罗辛联合杜他雄胺对实验动物褐家鼠Wistar菌株前列腺平滑肌细胞收缩力的影响表明，坦索罗辛给药6天，十二天,与阴性对照组相比，坦索罗辛联合一天的结果具有统计学意义（p=0.016；p=0.006；p=0.029）。此外,与坦索罗辛单药治疗6天和12天相比,坦索罗辛和度他雄胺联合治疗12天之间存在差异(p=0.160;p=0.010).
UNASSIGNED：连续给药单药坦洛新在第6至第12天具有上调作用。前列腺平滑肌细胞的收缩性下降发生在第一天，但在第六天至第十二天会增加。另一方面,我们的研究结果还表明，坦索罗辛和度他雄胺的组合具有降低收缩力的作用，并且在第12天最有效。
未经评估：我们的研究旨在确定长期服用坦索罗辛的效果，研究目的:探讨盐酸达雄胺与坦索罗辛-达雄胺联合应用对BPH模型大鼠前列腺平滑肌细胞收缩性的影响.
UNASSIGNED：本研究是使用仅实验后测试方法设计的，对照组设计。它测量了从实验动物的前列腺基质中获得的前列腺平滑肌细胞的收缩力成年雄性褐家鼠Wistar菌株诱导的BPH并给予坦索罗辛1mg/kg/天，dutasteride0.5mg/kg/天，以及连续给药1、6和12天的组合。如果数据分布正常，则使用单向ANOVA分析数据，如果数据分布异常，则使用KruskallWalis分析数据。
未经批准：坦索罗辛的作用，杜他雄胺和坦索罗辛联合杜他雄胺对实验动物褐家鼠Wistar菌株前列腺平滑肌细胞收缩力的影响表明，坦索罗辛给药6天，十二天,与阴性对照组相比，坦索罗辛联合一天的结果具有统计学意义（p=0.016；p=0.006；p=0.029）。此外,与坦索罗辛单药治疗6天和12天相比,坦索罗辛和度他雄胺联合治疗12天之间存在差异(p=0.160;p=0.010).
UNASSIGNED：连续给药单药坦洛新在第6至第12天具有上调作用。前列腺平滑肌细胞的收缩性下降发生在第一天，但在第六天至第十二天会增加。另一方面,我们的研究结果还表明，坦索罗辛和度他雄胺的组合具有降低收缩力的作用，并且在第12天最有效。
